These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25545243)

  • 1. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
    Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
    PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of IGF2BP2, KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen.
    Liu X; Chen Z; Zhao X; Huang M; Wang C; Peng W; Yin J; Li J; He G; Li X; Zhu X
    Pharmacogenomics; 2015; 16(9):959-70. PubMed ID: 26115082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen.
    Liu R; Huang M; Zhao X; Peng W; Sun S; Cao J; Ji D; Wang C; Guo W; Li J; Yin J; Zhu X
    Oncotarget; 2015 Nov; 6(36):39018-27. PubMed ID: 26528696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy?
    Seibold P; Hall P; Schoof N; Nevanlinna H; Heikkinen T; Benner A; Liu J; Schmezer P; Popanda O; Flesch-Janys D; Chang-Claude J
    Breast; 2013 Oct; 22(5):817-23. PubMed ID: 23489758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NQO1 rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M) polymorphisms segregate the risk of childhood acute leukemias according to age range distribution.
    de Aguiar Gonçalves BA; Vasconcelos GM; Thuler LC; Andrade C; Faro A; Pombo-de-Oliveira MS; ; Emerenciano M; de Camargo B; Bernstain L; Neves CC; Agareno JM; de Carvalho LM; Araújo FN; de Brito NP; Magalhães IQ; Cordoba JC; Pimenta F; Gadelha A; Cartaxo E; Basegio RM; Mnayarji A; Souza MS; Arencibia A; Melaragno R; Cóser VM; Lafayete TC; Koifman S
    Cancer Causes Control; 2012 Nov; 23(11):1811-9. PubMed ID: 22976839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
    J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.
    Oh SY; Shin A; Kim SG; Hwang JA; Hong SH; Lee YS; Kwon HC
    Oncotarget; 2016 May; 7(21):31204-14. PubMed ID: 27144430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
    Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
    Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
    Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
    Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
    Brieau B; Auzolle C; Pozet A; Tougeron D; Bouché O; Soibinet P; Coriat R; Prieux C; Lecomte T; Goujon G; Marthey L; Rougier P; Bonnetain F; Ducreux M; Taieb J; Zaanan A
    Dig Liver Dis; 2016 Apr; 48(4):441-5. PubMed ID: 26775096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Stenholm L; Stoehlmacher-Williams J; Al-Batran SE; Heussen N; Akin S; Pauligk C; Lehmann S; Senff T; Hofheinz RD; Ehninger G; Kramer M; Goekkurt E
    Ann Oncol; 2013 Oct; 24(10):2581-2588. PubMed ID: 23975664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer.
    Xu Z; Zhu H; Luk JM; Wu D; Gu D; Gong W; Tan Y; Zhou J; Tang J; Zhang Z; Wang M; Chen J
    Cancer; 2012 Nov; 118(22):5489-96. PubMed ID: 22517484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
    Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
    Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.
    Deng X; Yang X; Cheng Y; Liu X; Li X; Zhao R; Qin C; Lu Q; Yin C
    Sci Rep; 2015 Sep; 5():14000. PubMed ID: 26354850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.